Saxenda in Obesity Services (STRIVE Study)

  • Research type

    Research Study

  • Full title

    EFFECTIVENESS AND COST OF INTEGRATING A PROTOCOL WITH USE OF LIRAGLUTIDE 3.0 MG INTO AN OBESITY SERVICE: (STRIVE STUDY)

  • IRAS ID

    219773

  • Contact name

    Melanie Davies

  • Contact email

    melanie.davies@uhl-tr.nhs.uk

  • Sponsor organisation

    University of Leicester

  • Eudract number

    2016-004511-12

  • Duration of Study in the UK

    3 years, 2 months, 2 days

  • Research summary

    Adults with obesity are at increased risk of developing associated health complications compared to patients who are of normal weight. Liraglutide 3.0mg (Saxenda) has been recently approved for the treatment of obesity, which has demonstrated its safety and effectiveness. In people with obesity, Liraglutide 3.0mg (Saxenda) has been shown to improve blood pressure and diabetes control as well as to prevent diabetes development in those with prediabetes.

    However, Liraglutide 3.0mg (Saxenda) is not equally effective in all people with obesity and the high cost of the medication makes it less attractive to the health service for use routinely in obesity clinics. Previous studies have shown that approximately 14% of the people who will use the medication will be able to achieve more than 15% weight loss at one year after the treatment (“good” responders) and the vast majority of the “good” responders will achieve significant weight loss from the first months of treatment.

    The aim of this study is to investigate the effectiveness and cost-effectiveness of Liraglutide 3.0mg (Saxenda) in the obesity clinic settings with a protocol for targeted use of the medication in patients who are “early” and “good” responders to the treatment. This approach is expected to minimise the side-effects and unnecessary exposure of those who will not achieve significant weight loss with Liraglutide 3.0mg (Saxenda), optimise the costs of the medications and target the patients who will benefit more from its use.

  • REC name

    East of England - Cambridge Central Research Ethics Committee

  • REC reference

    17/EE/0208

  • Date of REC Opinion

    26 May 2017

  • REC opinion

    Unfavourable Opinion